Galderma Group AG (XSWX:GALD) Depreciation, Depletion and Amortization: CHF261 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
14 GF Score
Price CHF161.25
View Full Analysis

What is Galderma Group AG Depreciation, Depletion and Amortization?

Galderma Group AG XSWX:GALD +0.19% 14 Depreciation, Depletion and Amortization is CHF261 Mil as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100.

Galderma Group AG's depreciation, depletion and amortization for the six months ended in Jun. 2026 was CHF129 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Jun. 2026 was CHF261 Mil.


Galderma Group AG  (XSWX:GALD) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Galderma Group AG Depreciation, Depletion and Amortization Related Terms


Galderma Group AG Depreciation, Depletion and Amortization Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Depreciation, Depletion and Amortization Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Depreciation, Depletion and Amortization
228.11 265.22 248.39 258.04 268.25

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Depreciation, Depletion and Amortization Get a 7-Day Free Trial 126.33 131.65 136.22 131.96 129.05
XSWX:GALD
14GF Score
Galderma Group AG XSWX:GALD
Depreciation, Depletion and Amortization is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF261 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Depreciation, Depletion and Amortization of CHF261 Mil mean?
Galderma Group AG (XSWX:GALD) has a Depreciation, Depletion and Amortization of CHF261 Mil as of Jun. 2026. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Galderma Group AG.
Is Galderma Group AG's Depreciation, Depletion and Amortization too high?
Galderma Group AG's current Depreciation, Depletion and Amortization is CHF261 Mil. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Depreciation, Depletion and Amortization compare to ZTS and UTHR?
Galderma Group AG's Depreciation, Depletion and Amortization of CHF261 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Depreciation, Depletion and Amortization for a Drug Manufacturers company?
A good Depreciation, Depletion and Amortization depends on the Drug Manufacturers industry context. However, Depreciation, Depletion and Amortization should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Depreciation, Depletion and Amortization mean?
A high Depreciation, Depletion and Amortization can signal that a stock is expensive relative to its fundamentals. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Galderma Group AG. Galderma Group AG's current Depreciation, Depletion and Amortization is CHF261 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Depreciation, Depletion and Amortization of CHF261 Mil. The current Depreciation, Depletion and Amortization is CHF261 Mil. Galderma Group AG's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Depreciation, Depletion and Amortization calculated?
Depreciation, Depletion and Amortization is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Depreciation, Depletion and Amortization is CHF261 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score

Get the complete analysis for XSWX:GALD

Depreciation, Depletion and Amortization is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF161.25
Price